Proton or Photon RT for Retroperitoneal Sarcomas

Conditions

• Retroperitoneal Sarcoma

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• IG-IMPT — RADIATION
  Daily, Monday-Friday for about 6 weeks
• IG IMRT — RADIATION
  Daily, Monday-Friday for about 6 weeks

Study Details

This research study is a Phase I clinical trial. Phase I clinical trials test the safety of an investigational intervention. Phase I studies also try to define the appropriate dose of the investigational therapy to use for further studies. "Investigational" means that the intervention is still being studied and that research doctors are trying to find out more about it. Retroperitoneal sarcomas are soft tissue tumors located at the far back of the abdomen. Typically, patients with retroperitoneal sarcomas either have surgery for the removal of their tumors alone, or have their tumors removed, followed by standard radiation therapy, or have pre-operative radiation followed by surgery. When conventional radiation therapy is delivered after surgery, it can damage normal tissue. In this study, you will undergo proton beam radiation therapy or IMRT before undergoing surgery for the removal of your tumor. Proton radiation and IMRT are FDA approved radiation delivery systems. Protons are tiny particles with positive charge that can be controlled to travel a certain distance and stop inside the body. In theory, this allows better control of where the radiation dose is delivered as compared to photons. Since proton radiation is more targeted, it may help to reduce unwanted side effects from radiation. In this study, a standard dose of radiation will be given to the majority of the tumor, while a simultaneously integrated boost of additional radiation will be given to certain areas of the tumor identified as higher risk. This means that a higher radiation dose will be given to the higher risk areas of the tumor. The purpose of this study is to determine the highest dose of radiation therapy with protons or IMRT that can be delivered safely in patients with retroperitoneal sarcomas and the effectiveness of proton beam radiation therapy as an intervention for patients with retroperitoneal sarcomas.

Key Dates

Start date

Dec 31, 2012

Status verified

Mar 2026

Primary completion

Jun 30, 2027

Completion

Dec 31, 2027

Study Design

Enrollment

80 participants (estimated)

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Treatment Arm IMPT
  IG-IMPT with SIB to the high risk margin
• Experimental: Treatment Arm IMRT
  IG IMRT with SIB to the high risk margin

Primary Outcome Measure

Phase I: Determine MTD [ Time Frame: 2 years ]

Central Contacts

• Thomas DeLaney, MD
  617-726-6876
  [email protected]

Locations (10)

Find similar trials in Chicago, IL

Related Studies

• REtroperitoneal SArcoma Registry: an International Prospective Initiative
  Recruiting · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Los Angeles, California
• Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
  PHASE3 · Recruiting · European Organisation for Research and Treatment of Cancer - EORTC · Birmingham, Alabama
• Proton-Spatially Fractionated Radiotherapy and Standard Radiation Therapy for the Treatment of Newly Diagnosed Retroperitoneal Soft Tissue Sarcoma
  PHASE1/PHASE2 · Recruiting · Northwestern University · Chicago, Illinois
• Short Course Radiation Treatment for Patients With Primary or Locally Recurrent Retroperitoneal Sarcoma Prior to Surgery
  PHASE1 · Recruiting · Brigham and Women's Hospital · Boston, Massachusetts